Associations - FLT3 inhibitor

FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	quizartinib Sensitive: A1 - Approval quizartinib Sensitive : A1	quizartinib Sensitive: A1 - Approval quizartinib Sensitive : A1
No biomarker	Gastrointestinal Stromal Tumor	No biomarker	Gastrointestinal Stromal Tumor	ripretinib Sensitive: A1 - Approval ripretinib Sensitive : A1	ripretinib Sensitive: A1 - Approval ripretinib Sensitive : A1
No biomarker	Tenosynovial Giant Cell Tumor	No biomarker	Tenosynovial Giant Cell Tumor	pexidartinib Sensitive: A1 - Approval pexidartinib Sensitive : A1	pexidartinib Sensitive: A1 - Approval pexidartinib Sensitive : A1
PDGFRA exon 18 mutation	Gastrointestinal Stromal Tumor	PDGFRA exon 18 mutation	Gastrointestinal Stromal Tumor	ripretinib Sensitive: A2 - Guideline ripretinib Sensitive : A2	ripretinib Sensitive: A2 - Guideline ripretinib Sensitive : A2
No biomarker	Acute Myelogenous Leukemia	No biomarker	Acute Myelogenous Leukemia	FLT3 inhibitor Sensitive: B - Late Trials FLT3 inhibitor Sensitive : B	FLT3 inhibitor Sensitive: B - Late Trials FLT3 inhibitor Sensitive : B
KIT mutation	Gastrointestinal Stromal Tumor	KIT mutation	Gastrointestinal Stromal Tumor	ripretinib Sensitive: B - Late Trials ripretinib Sensitive : B	ripretinib Sensitive: B - Late Trials ripretinib Sensitive : B
PDGFRA mutation	Gastrointestinal Stromal Tumor	PDGFRA mutation	Gastrointestinal Stromal Tumor	ripretinib Sensitive: B - Late Trials ripretinib Sensitive : B	ripretinib Sensitive: B - Late Trials ripretinib Sensitive : B
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	FLT3 inhibitor Sensitive: B - Late Trials FLT3 inhibitor Sensitive : B	FLT3 inhibitor Sensitive: B - Late Trials FLT3 inhibitor Sensitive : B
KMT2A rearrangement	Acute Lymphocytic Leukemia	KMT2A rearrangement	Acute Lymphocytic Leukemia	CEP-701 Sensitive: B - Late Trials CEP-701 Sensitive : B	CEP-701 Sensitive: B - Late Trials CEP-701 Sensitive : B
KIT exon 17 mutation	Gastrointestinal Stromal Tumor	KIT exon 17 mutation	Gastrointestinal Stromal Tumor	ripretinib Sensitive: B - Late Trials ripretinib Sensitive : B	ripretinib Sensitive: B - Late Trials ripretinib Sensitive : B
KIT exon 13 mutation	Gastrointestinal Stromal Tumor	KIT exon 13 mutation	Gastrointestinal Stromal Tumor	ripretinib Sensitive: B - Late Trials ripretinib Sensitive : B	ripretinib Sensitive: B - Late Trials ripretinib Sensitive : B
KIT exon 9 mutation	Gastrointestinal Stromal Tumor	KIT exon 9 mutation	Gastrointestinal Stromal Tumor	ripretinib Sensitive: B - Late Trials ripretinib Sensitive : B	ripretinib Sensitive: B - Late Trials ripretinib Sensitive : B
KIT exon 11 mutation	Gastrointestinal Stromal Tumor	KIT exon 11 mutation	Gastrointestinal Stromal Tumor	ripretinib Sensitive: B - Late Trials ripretinib Sensitive : B	ripretinib Sensitive: B - Late Trials ripretinib Sensitive : B
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	HM43239 Sensitive: B - Late Trials HM43239 Sensitive : B	HM43239 Sensitive: B - Late Trials HM43239 Sensitive : B
KIT exon 18 mutation	Gastrointestinal Stromal Tumor	KIT exon 18 mutation	Gastrointestinal Stromal Tumor	ripretinib Sensitive: B - Late Trials ripretinib Sensitive : B	ripretinib Sensitive: B - Late Trials ripretinib Sensitive : B
IDH2 mutation	Glioma	IDH2 mutation	Glioma	TG02 Sensitive: C2 – Inclusion Criteria TG02 Sensitive : C2	TG02 Sensitive: C2 – Inclusion Criteria TG02 Sensitive : C2
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	quizartinib + RAIN-32 Sensitive: C2 – Inclusion Criteria quizartinib + RAIN-32 Sensitive : C2	quizartinib + RAIN-32 Sensitive: C2 – Inclusion Criteria quizartinib + RAIN-32 Sensitive : C2
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	quizartinib Sensitive: C2 – Inclusion Criteria quizartinib Sensitive : C2	quizartinib Sensitive: C2 – Inclusion Criteria quizartinib Sensitive : C2
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	ARO-002 Sensitive: C2 – Inclusion Criteria ARO-002 Sensitive : C2	ARO-002 Sensitive: C2 – Inclusion Criteria ARO-002 Sensitive : C2
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	CEP-701 Sensitive: C2 – Inclusion Criteria CEP-701 Sensitive : C2	CEP-701 Sensitive: C2 – Inclusion Criteria CEP-701 Sensitive : C2
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	PHI-101 Sensitive: C2 – Inclusion Criteria PHI-101 Sensitive : C2	PHI-101 Sensitive: C2 – Inclusion Criteria PHI-101 Sensitive : C2
FLT3 mutation	Myelodysplastic Syndrome	FLT3 mutation	Myelodysplastic Syndrome	ARO-002 Sensitive: C2 – Inclusion Criteria ARO-002 Sensitive : C2	ARO-002 Sensitive: C2 – Inclusion Criteria ARO-002 Sensitive : C2
FLT3 D835	Acute Myelogenous Leukemia	FLT3 D835	Acute Myelogenous Leukemia	ARO-002 Sensitive: C2 – Inclusion Criteria ARO-002 Sensitive : C2	ARO-002 Sensitive: C2 – Inclusion Criteria ARO-002 Sensitive : C2
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	pexidartinib Sensitive: C2 – Inclusion Criteria pexidartinib Sensitive : C2	pexidartinib Sensitive: C2 – Inclusion Criteria pexidartinib Sensitive : C2
PDGFRA D842V	Gastrointestinal Stromal Tumor	PDGFRA D842V	Gastrointestinal Stromal Tumor	ARO-002 Sensitive: C2 – Inclusion Criteria ARO-002 Sensitive : C2	ARO-002 Sensitive: C2 – Inclusion Criteria ARO-002 Sensitive : C2
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	quizartinib + RAIN-32 Sensitive: C2 – Inclusion Criteria quizartinib + RAIN-32 Sensitive : C2	quizartinib + RAIN-32 Sensitive: C2 – Inclusion Criteria quizartinib + RAIN-32 Sensitive : C2
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	venetoclax + quizartinib Sensitive: C2 – Inclusion Criteria venetoclax + quizartinib Sensitive : C2	venetoclax + quizartinib Sensitive: C2 – Inclusion Criteria venetoclax + quizartinib Sensitive : C2
IDH2 mutation	Acute Myelogenous Leukemia	IDH2 mutation	Acute Myelogenous Leukemia	MEN1703 Sensitive: C2 – Inclusion Criteria MEN1703 Sensitive : C2	MEN1703 Sensitive: C2 – Inclusion Criteria MEN1703 Sensitive : C2
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	FLT3 inhibitor + gilteritinib Sensitive: C2 – Inclusion Criteria FLT3 inhibitor + gilteritinib Sensitive : C2	FLT3 inhibitor + gilteritinib Sensitive: C2 – Inclusion Criteria FLT3 inhibitor + gilteritinib Sensitive : C2
FLT3 mutation	Myelodysplastic Syndrome	FLT3 mutation	Myelodysplastic Syndrome	quizartinib Sensitive: C2 – Inclusion Criteria quizartinib Sensitive : C2	quizartinib Sensitive: C2 – Inclusion Criteria quizartinib Sensitive : C2
CBL mutation	Myelodysplastic Syndrome	CBL mutation	Myelodysplastic Syndrome	quizartinib Sensitive: C2 – Inclusion Criteria quizartinib Sensitive : C2	quizartinib Sensitive: C2 – Inclusion Criteria quizartinib Sensitive : C2
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	CA-4948 Sensitive: C2 – Inclusion Criteria CA-4948 Sensitive : C2	CA-4948 Sensitive: C2 – Inclusion Criteria CA-4948 Sensitive : C2

FLT3 inhibitor

FLT3 inhibitor

Associations(185)

Associations
(185)